|
1
|
|
|
2
|
Metformin accumulation without hyperlactataemia and metformin-induced hyperlactataemia without metformin accumulation. DIABETES & METABOLISM 2014; 40:220-3. [DOI: 10.1016/j.diabet.2013.12.003] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/20/2013] [Revised: 12/02/2013] [Accepted: 12/10/2013] [Indexed: 12/23/2022]
|
|
3
|
HICKLER RB, LAULER DP, THORN GW. Plasma angiotensinase activity in patients with hypertension and edema. J Clin Invest 1998; 42:635-48. [PMID: 13961132 PMCID: PMC289328 DOI: 10.1172/jci104754] [Citation(s) in RCA: 49] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
|
5
|
Barraclough MA, Bacchus B, Brown JJ, Davies DL, Lever AF, Robertson JI. Plasma-renin and aldosterone secretion in hypertensive patients with renal or renal artery lesions. Lancet 1965; 2:1310-3. [PMID: 4165303 DOI: 10.1016/s0140-6736(65)92338-x] [Citation(s) in RCA: 33] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
|
6
|
|
|
8
|
ULRYCH M, HOFMAN J, HEJL Z. Cardiac and renal hyperresponsiveness to acute plasma volume expansion in hypertension. Am Heart J 1964; 68:193-203. [PMID: 14204314 DOI: 10.1016/0002-8703(64)90040-7] [Citation(s) in RCA: 31] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
|
9
|
|
|
11
|
LAAS H, BETZIEN G, BRANCHRZ H. �ber die antihypertensive Wirkung der elektrolytwirksamen Substanzen Isobutylhydrochlorothiazid, Spironolactone und Triamterene. J Mol Med (Berl) 1963; 41:961-7. [PMID: 14092949 DOI: 10.1007/bf01478541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
|
12
|
Abstract
1. I
131
-labeled angiotensin II has been employed to study the metabolism of this polypeptide.
2. Following the intravenous administration of angiotensin II-I
131
to normotensive and untreated primary benign hypertensive subjects, a slower angiotensin II degradation rate and a larger final volume of distribution of angiotensin II-I
131
was found in the hypertensive than in the normotensive patients. The slow rate of degradation of angiotensin II may be responsible for the increased quantity and concentration of this polypeptide in the body fluids.
3. Greater quantities of angiotensin II-I
131
are degraded in vitro by sera from untreated primary benign hypertensive patients than from normotensive or secondary renal hypertensive patients. There is evidence for the presence of a serum factor or factors enhancing angiotensin II-I
131
degradation and for the presence of a heat labile inhibitor.
Collapse
|